全球小分子 CMO 市场规模（按应用、地区、范围和预测）

小分子CMO市场规模及预测

2024 年小分子 CMO 市场规模价值 478 亿美元，预计到 2031 年将达到 840 亿美元，在 2024-2031 年预测期内的复合年增长率为 5.8%。製药业的成长和对抗癌药物的需求不断增加是推动市场成长的主要因素。全球小分子 CMO 市场报告对市场进行了全面的评估。它对关键细分市场、趋势、市场推动因素、阻碍因素、竞争格局以及在市场中发挥关键作用的因素进行了全面分析。

定义全球小分子 CMO 市场

CMO 代表合约製造组织。CMO 也称为合约开发和製造组织 (CDMO)。它是一个以合约方式向製药业的其他公司提供服务的组织，提供从药物开发到药物製造的综合服务。小分子主要是在实验室中分离或重新合成的天然化合物。这些可以互换地称为药物。大多数药物都属于小分子类别。小分子定义明确，且与製造製程无关。

製药业受到产能短缺和过剩週期的影响，不只是合约製造商如此，内部製造商也是如此。因此，对于合约製造组织（CMO）来说，在产能扩张和合作伙伴选择方面做出审慎的决定非常重要。CMO 提供的 "一站式服务" 预计将影响其成长，因为它有助于扩大产品组合。大型 CMO 正在顺应扩张的趋势，并专注于生物製药和药物开发的细分领域。这些公司专注于建立基因改造产品开发的监管途径。

全球小分子 CMO 市场概览

製药业的成长和对抗癌药物的需求不断增加是推动市场成长的主要因素。其他成长因素，如对製程开发 CMO 服务的需求不断增长、小分子药物通路强劲、 FDA 批准率不断上升、併购以及对提供高效 API 的 CDMO 的需求不断增长，预计也将在不久的将来推动市场成长。

此外，采用外包所带来的成本和时间节省也有助于推动产业成长。公司正在投资基础设施、人才和技术，以获取更大的外包收入占有率。预计生物製剂专利到期将促使需求增加。此外，在综合或风险共担商业模式中提供加值服务的端到端服务提供者的存在也有望推动该产业的发展。

此外，新产品的推出和新的药物输送机制预计将推动外包需求。该行业正在经历产能短缺和过剩的交替循环，不仅是合约製造商如此，内部製造商也同样如此。因此，对于合约製造组织（CMO）来说，在产能扩张和合作伙伴选择方面做出审慎的决定非常重要。

然而，目前全球 CMO 的商业模式面临许多课题和复杂性。市场分散、定价压力、产量下降、新技术以及早期公司缺乏风险投资 (VC) 资金等因素导致 CMO 支出有可能降至经济衰退水平以下。

目录

第1章 全球小分子CMO市场简介

• 市场概况
• 调查范围
• 先决条件

第 2 章 执行摘要

第3章 VERIFIED MARKET RESEARCH研究方法

• 数据挖掘
• 验证
• 一次资料
• 数据源列表

第4章 全球小分子CMO市场展望

• 概述
• 市场动态
  • 促进因素
  • 阻碍因素
  • 机会
• 波特的五力模型
• 价值链分析

第5章 全球小分子 CMO 市场（依应用）

• 概述
• 心血管
• 肿瘤
• 糖尿病
• 免疫性疾病

第6章 全球小分子 CMO 市场（按地区）

• 概述
• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 亚太其他地区
• 世界其他地区
  • 拉丁美洲
  • 中东/非洲

第7章全球小分子CMO市场竞争格局

• 概述
• 各公司市场排名
• 主要发展策略

第8章 公司简介

• Lonza Group
• Wuxi AppTec Co. Ltd.
• Catalent Inc
• Patheon Inc.
• Cambrex
• SIEGFRID
• WuXi Biologics
• Groupe PCAS

第9章 附录

第10章 相关报导

Small Molecule CMO Market Size And Forecast

Small Molecule CMO Market size was valued at USD 47.8 Billion in 2024 and is projected to reach USD 84.0 Billion by 2031, growing at a CAGR of 5.8% during the forecast period 2024-2031. The growing pharmaceutical industry and rising demand for oncology drugs are the major factors that are driving the growth of the market. The Global Small Molecule CMO Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Small Molecule CMO Market Definition

CMO states contract manufacturing organization. CMO is also called contract development and manufacturing organization (CDMO). It is an organization that serves other companies in the pharmaceutical industry on a contract basis to make available comprehensive services from drug development through drug manufacturing. completion of projects and subsequent regulatory submission. Small molecules are primarily made up of naturally occurring compounds that have been isolated or re-synthesized in the laboratory. These are interchangeably called drugs. The majority of drugs have come under the category of small molecules. Small molecules are well defined and independent of the manufacturing process.

The industry has been alternating between the cycles of inadequate and excessive production capacity for the contract as well as captive manufacturers. Hence, it is important for Contract Manufacturing Organizations (CMOs) to make cautious decisions pertaining to capacity expansion and choice of deals. One-stop-shop" offered by the CMO's for the promotion of a portfolio of a complete range of products is anticipated to influence the growth of CMO's. The larger CMOs are embracing the trend of moving and focusing on the niche areas of biopharmaceutical and pharmaceutical development. They are focusing on the establishment of regulatory pathways for transgenic-based product development.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Small Molecule CMO Market Overview

The growing pharmaceutical industry and rising demand for oncology drugs are the major factors that are driving the growth of the market. Other growth drivers such as growing demand for process development CMO services, robust pipeline of small molecule drugs & increasing rate of FDA approvals, mergers & acquisitions, growing demand for CDMOs offering highly potent API etc. are expected to boost the growth of the market in the near future.

In addition, Cost saving and time-saving benefits associated with the implementation of outsourcing is responsible for driving industrial growth. Companies are investing in infrastructure, personnel, and technology in order to gain a significant share of the outsourcing revenue. Increasing demand as a consequence of the ongoing patent cliff of the biologic drugs is expected to fuel demand. Furthermore, the Presence of end-to-end service providers that are engaged in providing value-added services for an integrated or risk-sharing business model is expected to bolster progress in this industry.

Moreover, new product launches and novel drug delivery mechanisms are anticipated to drive outsourcing demand. The industry has been alternating between the cycles of inadequate and excessive production capacity for the contract as well as captive manufacturers. Hence, it is important for Contract Manufacturing Organizations (CMOs) to make cautious decisions pertaining to capacity expansion and choice of deals.

However, there are several challenges and complications allied with the present business model of CMOs globally. The fragmented nature of the market combined with price pressure, lower unit volumes and new technologies and lack of Venture Capitalist (VC) funding for early-stage companies have resulted in less expenditure than precession levels which is likely to pose a threat to CMOs.

Global Small Molecule CMO Market: Segmentation Analysis

The Global Small Molecule CMO Market is Segmented on the basis of Application, and Geography.

Small Molecule CMO Market, By Application

• Cardiovascular
• Oncology
• Diabetes
• Immunological Disorders
• Based on Application, the market is bifurcated into Cardiovascular, Oncology, Diabetes, and Immunological Disorders. Immunological Disorders are likely to register the highest CAGR over the forecast period. API dominated with respect to revenue as a consequence of the rising demand for
• High Potency Active Pharmaceutical Ingredients (HPAPI)
• . Market entities are engaged in the development of large-scale mfg. facilities on the pilot as well as commercial scale.

Small Molecule CMO Market, By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Rest of the World
• On the basis of regional analysis, The Global Small Molecule CMO Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America dominated with respect to revenue share in 2016, however, Asia Pacific is projected to grow at a surplus rate. This growth is supported by rising in the number of companies outsourcing projects in the developing economies of this region. A larger share of the North American region is a consequence of the expansion of the U.S. healthcare industry. This share is anticipated to decrease to a substantial extent thus driving the share of BRIC countries in this sector

Key Players

• The "Global Small Molecule CMO Market" study report will provide a valuable insight with an emphasis on the global market including some of the major players such as
• Lonza Group, Wuxi AppTec Co. Ltd., Catalent Inc, Patheon Inc., Cambrex, SIEGFRID, WuXi Biologics, Groupe PCAS.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• Partnerships, Collaborations and Agreements
• On July 2020, Viatris extended its partnership with Gilead to build COVID-19 treatments by announcing a global agreement with the company to commercial Remdesivir in 127 low- and middle-income countries. The drug was launched under the brand name DESREM in India. Viatris has a long-standing history of partnering with Gilead Sciences to tackle critical public health issues in India and worldwide, beginning with expanding access to high-quality, affordable HIV/AIDS antiretrovirals.
• On June 2021, Eisai Co., Ltd. and Bristol-Myers Squibb Company announced a global strategic partnership agreement to develop and commercialize MORAb-202, an antibody-drug combination. MORAb-202 will be developed and commercialized jointly by Eisai and Bristol Myers Squibb under the terms of the agreement. Eisai would remain responsible for the manufacturing and supply of MORAb-202 globally.
• On August 2021, Cipla Limited and Kemwell Biopharma Private Limited, a biopharmaceutical Contract Development and Manufacturing Organization announced a joint venture agreement to develop, manufacture and commercialize biosimilars for global markets. Under the terms of the agreement, the joint venture would leverage Cipla and Kemwell's complementary strengths for end-to-end product development, clinical development, regulatory filings, manufacturing, and commercialization of biopharmaceutical products.
• Mergers and Acquisitions
• On July 2020, US-based Advent International agreed to acquire a controlling stake in RA Chem Pharma from its parent Micro Labs. Another US-based giant, KKR, also agreed to acquire a 54% stake in JB Chemicals and Pharmaceuticals for USD 611 million.
• Product Launches and Product Expansions
• On December 2020, Viatris sponsored the Panacea event in India and Narayana Health, Ayush Society, to improve focus on mental health improvement in India. It conducts a series of virtual sessions on yoga, stress management, nutrition, and mental health to help patients overcome post-COVID-19 anxiety, fear, and mental trauma. Special sessions were conducted by renowned pulmonologists, neurologists, and cardiologists.

TABLE OF CONTENTS

1. INTRODUCTION OF GLOBAL SMALL MOLECULE CMO MARKET

• 1.1. Overview of the Market
• 1.2. Scope of Report
• 1.3. Assumptions

2. EXECUTIVE SUMMARY

3. RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1. Data Mining
• 3.2. Validation
• 3.3. Primary Interviews
• 3.4. List of Data Sources

4. GLOBAL SMALL MOLECULE CMO MARKET OUTLOOK

• 4.1. Overview
• 4.2. Market Dynamics
  • 4.2.1. Drivers
  • 4.2.2. Restraints
  • 4.2.3. Opportunities
• 4.3. Porters Five Force Model
• 4.4. Value Chain Analysis

5. GLOBAL SMALL MOLECULE CMO MARKET, BY APPLICATION

• 5.1. Overview
• 5.2. Cardiovascular
• 5.3. Oncology
• 5.4. Diabetes
• 5.5. Immunological Disorders

6. GLOBAL SMALL MOLECULE CMO MARKET, BY GEOGRAPHY

• 6.1. Overview
• 6.2. North America
  • 6.2.1. U.S.
  • 6.2.2. Canada
  • 6.2.3. Mexico
• 6.3. Europe
  • 6.3.1. Germany
  • 6.3.2. U.K.
  • 6.3.3. France
  • 6.3.4. Rest of Europe
• 6.4. Asia Pacific
  • 6.4.1. China
  • 6.4.2. Japan
  • 6.4.3. India
  • 6.4.4. Rest of Asia Pacific
• 6.5 Rest of the World
  • 6.5.1 Latin America
  • 6.5.2 Middle East & Africa

7. GLOBAL SMALL MOLECULE CMO MARKET COMPETITIVE LANDSCAPE

• 7.1. Overview
• 7.2. Company Market Ranking
• 7.3. Key Development Strategies

8. COMPANY PROFILES

• 8.1. Lonza Group
  • 8.1.1. Overview
  • 8.1.2. Financial Performance
  • 8.1.3. Product Outlook
  • 8.1.4. Key Developments
• 8.2. Wuxi AppTec Co. Ltd.
  • 8.2.1. Overview
  • 8.2.2. Financial Performance
  • 8.2.3. Product Outlook
  • 8.2.4. Key Developments
• 8.3. Catalent Inc
  • 8.3.1. Overview
  • 8.3.2. Financial Performance
  • 8.3.3. Product Outlook
  • 8.3.4. Key Developments
• 8.4. Patheon Inc.
  • 8.4.1. Overview
  • 8.4.2. Financial Performance
  • 8.4.3. Product Outlook
  • 8.4.4. Key Developments
• 8.5. Cambrex
  • 8.5.1. Overview
  • 8.5.2. Financial Performance
  • 8.5.3. Product Outlook
  • 8.5.4. Key Developments
• 8.6. SIEGFRID
  • 8.6.1. Overview
  • 8.6.2. Financial Performance
  • 8.6.3. Product Outlook
  • 8.6.4. Key Developments
• 8.7. WuXi Biologics
  • 8.7.1. Overview
  • 8.7.2. Financial Performance
  • 8.7.3. Product Outlook
  • 8.7.4. Key Developments
• 8.8. Groupe PCAS
  • 8.8.1. Overview
  • 8.8.2. Financial Performance
  • 8.8.3. Product Outlook
  • 8.8.4. Key Developments

9. Appendix

10. Related Reports